Savara Pharmaceuticals Announces FDA Grant of Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Its Lead Product, AeroVanc<

Savara Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has designated the Company‚Äôs lead antibiotic product, AeroVanc, as a Qualified Infectious Disease Product (QIDP) for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic … Continued